Recently, Tianjin Exosome Technology Co., Ltd. collaborated with the China National Institute of Food and Drug Control and the China Drug Review Center, among others, to jointly submit a project titled "R&D and Regulatory Evaluation Technology for Stem Cells and Their Derivatives," which has received support from the 2024 National Key R&D Project "Stem Cell Research and Organ Repair" Special Project!The combination and joint application of exosomes and stem cells is advancing at an astonishing pace! In the future, the company will continue to deepen its research and development in the technology for the combined application of exosomes and stem cells, contributing more to the progress of biotechnology in our country.
The National Key R&D Program is the highest-level research and development project currently in our country, aimed at significant public welfare research concerning the national economy and people's livelihood, as well as strategic, fundamental, and forward-looking major scientific issues, and critical common key technologies and products related to the core competitiveness of the industry, overall independent innovation capability, and national security. This program continuously provides support and guidance for the main areas of national economic and social development. Among these, two key projects, 'stem cell research and organ repair' and 'cutting-edge biotechnology', have attracted significant attention, bringing considerable positive benefits to the cell health industry. The introduction of this policy not only signifies that our country's scientific research and technological innovation in the field of stem cells will reach a new level but also indicates the promising prospects for the broad application of stem cell technology in health security and medical research.
